HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (26) Citing Articles via Google Scholar Google Scholar Articles by Morgenthaler, N. G. Articles by Bergmann, A. Search for Related Content PubMed PubMed Citation Articles by Morgenthaler, N. G. Articles by Bergmann, A. Related Collections Proteomics and Protein Markers

Immunoluminometric Assay for the Midregion of Pro-Atrial Natriuretic Peptide in Human Plasma

¹ Research Department, B.R.A.H.M.S AG, Biotechnology Centre Hennigsdorf/Berlin, 16761 Hennigsdorf, Germany

^aauthor for correspondence: fax 49-3302-883-451, e-mail n.morgenthaler@brahms.de

The first 20% of the full text of this article appears below.

The prohormone of atrial natriuretic peptide (proANP) is a polypeptide of 126 amino acids. Mature atrial natriuretic peptide (ANP) consists of amino acids 99–126 and comprises 98% of the natriuretic peptides in the circulation (1). The N-terminal portion of proANP, termed proANP1–98 or NT-proANP, has a much longer half-life than mature ANP and has therefore been suggested to be a more reliable analyte for measurement than mature ANP (2). In addition to other established indications, proANP has recently gained much interest as a potential new marker in the field of sepsis (3), emphasizing the need for a reliable assay for this molecule.

All sandwich immunoassays developed for proANP to date use an antibody against the N-terminal region of proANP1–98 combined with a second antibody against either the midregion (4) or C-terminal region (5)(6). However, under certain conditions, the N-terminal region might be minimally accessible for antibody binding (7)(8). Despite the described long half-life of proANP, results from various competitive immunoassays as well as HPLC analyses indicate that proANP1–98 can be subject to further fragmentation (9)(10).

We developed a new sandwich immunoassay for midregional proANP (amino acids 53–90; Fig. 1A ). With this assay, which was named B.R.A.H.M.S SERISTRA® (B.R.A.H.M.S AG), we measured proANP values in 325 healthy controls.

View larger version (19K): [in this window] [in a new window]   Figure 1. Representation of the assay principle for midregional proANP (A), and interassay imprecision for 25 plasma samples measured on 10 different days (B). (A), numbers indicate amino acids (aa). (B), the interassay CV . . . [Full Text of this Article]

The following articles in journals at HighWire Press have cited this article:

				S. Q. Khan, O. Dhillon, D. Kelly, I. B. Squire, J. Struck, P. Quinn, N. G. Morgenthaler, A. Bergmann, J. E. Davies, and L. L. Ng Plasma N-Terminal B-Type Natriuretic Peptide as an Indicator of Long-Term Survival After Acute Myocardial Infarction: Comparison With Plasma Midregional Pro-Atrial Natriuretic Peptide: The LAMP (Leicester Acute Myocardial Infarction Peptide) Study J. Am. Coll. Cardiol., May 13, 2008; 51(19): 1857 - 1864. [Abstract] [Full Text] [PDF]

				M. Masia, J. Papassotiriou, N. G. Morgenthaler, I. Hernandez, C. Shum, and F. Gutierrez Midregional Pro-A-Type Natriuretic Peptide and Carboxy-Terminal Provasopressin May Predict Prognosis in Community-Acquired Pneumonia Clin. Chem., December 1, 2007; 53(12): 2193 - 2201. [Abstract] [Full Text] [PDF]

				S. von Haehling, E. A. Jankowska, N. G. Morgenthaler, C. Vassanelli, L. Zanolla, P. Rozentryt, G. S. Filippatos, W. Doehner, F. Koehler, J. Papassotiriou, et al. Comparison of Midregional Pro-Atrial Natriuretic Peptide With N-Terminal Pro-B-Type Natriuretic Peptide in Predicting Survival in Patients With Chronic Heart Failure J. Am. Coll. Cardiol., November 13, 2007; 50(20): 1973 - 1980. [Abstract] [Full Text] [PDF]

				G. Szinnai, N. G. Morgenthaler, K. Berneis, J. Struck, B. Muller, U. Keller, and M. Christ-Crain Changes in Plasma Copeptin, the C-Terminal Portion of Arginine Vasopressin during Water Deprivation and Excess in Healthy Subjects J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3973 - 3978. [Abstract] [Full Text] [PDF]

				M. Christ-Crain and B. Muller Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators Eur. Respir. J., September 1, 2007; 30(3): 556 - 573. [Abstract] [Full Text] [PDF]

				J. Papassotiriou, N. G. Morgenthaler, J. Struck, C. Alonso, and A. Bergmann Immunoluminometric Assay for Measurement of the C-Terminal Endothelin-1 Precursor Fragment in Human Plasma Clin. Chem., June 1, 2006; 52(6): 1144 - 1151. [Abstract] [Full Text] [PDF]

				A. Gegenhuber, J. Struck, W. Poelz, R. Pacher, N. G. Morgenthaler, A. Bergmann, M. Haltmayer, and T. Mueller Midregional Pro-A-Type Natriuretic Peptide Measurements for Diagnosis of Acute Destabilized Heart Failure in Short-of-Breath Patients: Comparison with B-Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP Clin. Chem., May 1, 2006; 52(5): 827 - 831. [Abstract] [Full Text] [PDF]

				N. G. Morgenthaler, J. Struck, C. Alonso, and A. Bergmann Assay for the Measurement of Copeptin, a Stable Peptide Derived from the Precursor of Vasopressin Clin. Chem., January 1, 2006; 52(1): 112 - 119. [Abstract] [Full Text] [PDF]

				N. G. Morgenthaler, J. Struck, C. Alonso, and A. Bergmann Measurement of Midregional Proadrenomedullin in Plasma with an Immunoluminometric Assay Clin. Chem., October 1, 2005; 51(10): 1823 - 1829. [Abstract] [Full Text] [PDF]